Drug Trial Radar · NCT06673056
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 18, 2025
Primary completion
Dec 31, 2027
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- IntraBio IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Ataxia-Telangiectasia (A-T). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.
Conditions
- Ataxia-Telangiectasia
- Ataxia-Telangiectasia (A-T)
Interventions
N-Acetyl-L-LeucineDrug
N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
PlaceboOther
Matching Placebo Sachet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Scale for the Assessment and Rating of AtaxiaTime frame: End of Period I (week 12) vs. End of Period 2 (week 24)
Locations
11 sites in 6 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
Massachusetts General Hospital
Boston, Massachusetts
The University of Texas Health (UT Health)
Houston, Texas
University of Cologne
Cologne, Germany
University of Giessen
Giessen, Germany
Comenius University Bratislava
Bratislava, Slovakia
University Hospital L. Pasteur
Košice, Slovakia
Hospital Universitario La Paz
Madrid, Spain
University of Bern
Bern, Switzerland
Royal Papworth Hospital
Cambridge, United Kingdom
University of Nottingham
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.